<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940414-0-00030</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  April 14, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4700 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <CFRNO>21 CFR Part 520</CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE> Oral Dosage Form New Animal Drugs; Enalapril Maleate Tablets</DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Final rule. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the approval of a new animal drug application (NADA) filed by Merck Research Laboratories, Division of Merck &amp; Co., Inc. The NADA provides for the oral use of ENACARD <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=5 f=1 --> TM <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  (enalapril maleate) tablets for the treatment of heart failure in dogs. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  April 14, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Marcia K. Larkins, Center for Veterinary Medicine (HFV&hyph;112), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;0614. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Merck Research Laboratories, Division of Merck &amp; Co., Inc., P.O. Box 2000, Rahway, NJ 07065, filed NADA 141&hyph;015 which provides for the use of ENACARD <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=5 f=1 --> TM <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  containing 1, 2.5, 5, 10, or 20 milligrams (mg) of enalapril maleate per (/) tablet. ENACARD <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=5 f=1 --> TM <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  tablets are administered to dogs once daily at a dosage of 0.5 mg/kilogram (kg) or twice daily at 0.5 mg/kg for a total daily dose of 1.0 mg/kg for the treatment of mild, moderate, and severe (modified New York Heart Association Class II, III, IV) heart failure in dogs. The NADA is approved as of February 24, 1994, and the regulations are amended in part 558 (21 CFR part 558) by adding new &sect;520.804 to reflect the approval. The basis of approval is discussed in the freedom of information summary. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and &sect;514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  Section 512(c)(2)(F)(i) of the Federal Food, Drug, and Cosmetic Act provides a 5-year period of exclusivity to this original NADA beginning February 24, 1994, because no active ingredient (including any ester or salt of the active ingredient) has been approved in any other application under section 512(b)(1) of the act. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 -->  List of Subjects in 21 CFR Part 520 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Animal drugs.  <!-- PJG 0012 frnewline -->   Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 520_ORAL DOSAGE FORM NEW ANIMAL DRUGS  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  1. The authority citation for 21 CFR part 520 continues to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority: <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 -->  2. New &sect;520.804 is added to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;520.804  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Enalapril tablets. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Specifications <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Each tablet contains either 1.0, 2.5, 5.0, 10.0, or 20.0 milligrams of enalapril maleate. <!-- PJG 0012 frnewline -->  (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sponsor <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . See 000006 in &sect;510.600(c) of this chapter. <!-- PJG 0012 frnewline -->  (c)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Conditions of use <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1) Dogs. (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Amount <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . 0.5 to 1.0 milligram of enalapril maleate per kilogram of body weight per day.  <!-- PJG 0012 frnewline -->  (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Indications for use <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Treatment of mild, moderate, and severe (modified New York Heart Association Class II, III, IV) heart failure in dogs. <!-- PJG 0012 frnewline -->  (iii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Limitations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Use 0.5 milligram per kilogram once daily. In the absence of adequate clinical response within a 2-week period, use may be increased to twice daily (a total of 1.0 milligram per kilogram). Enalapril maleate is administered as conjunctive therapy with furosemide and digoxin in the treatment of dilated cardiomyopathy and furosemide with or without digoxin in the treatment of chronic valvular disease. The safety of enalapril for use in breeding dogs has not been established. Use in pregnant bitches is not recommended. Federal law restricts this drug to use by or on the order of a licensed veterinarian. <!-- PJG 0012 frnewline -->  (2) [Reserved] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: April 8, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 -->  Richard H. Teske, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 -->  Acting Director, Center for Veterinary Medicine. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;9048 Filed 4&hyph;13&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            